ezetimibe has been researched along with Vascular Diseases in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Mikhailidis, DP; Paraskevas, KI; Saba, L; Suri, JS | 1 |
| Blazing, M; Bonaca, MP; Braunwald, E; Cannon, C; Giugliano, R; Gutierrez, JA; Park, JG; Tershakovec, A; White, J | 1 |
| Cavasin, MA; Chonchol, M; Demos-Davies, KM; Jablonski, K; Keenan, AL; Kendrick, J; Levi, M; Masuda, M; Masuda, R; McKinsey, TA; Miyazaki, M; Miyazaki-Anzai, S; Saunders, SJ | 1 |
| Drozd, VIu; Haĭdychuk, VS; Khukhlina, OS; Kosar, LIu; Mandryk, OIe | 1 |
| Baigent, C; Cass, A; Emberson, J; Gray, A; Haynes, R; Herrington, W; Landray, MJ; Mihaylova, B; Morton, RL; Schlackow, I; Staplin, N | 1 |
| Braga, MF; Gupta, M; Herjikaka, S; Kajil, M; Quan, A; Szmitko, PE; Teoh, H; Tsigoulis, M; Verma, S | 1 |
2 trial(s) available for ezetimibe and Vascular Diseases
| Article | Year |
|---|---|
Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial.
Topics: Acute Coronary Syndrome; Aged; Anticholesteremic Agents; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prognosis; Vascular Diseases | 2018 |
Impact of Educational Attainment on Health Outcomes in Moderate to Severe CKD.
Topics: Aged; Anticholesteremic Agents; Disease Progression; Educational Status; Ezetimibe; Female; Humans; Male; Middle Aged; Prospective Studies; Renal Insufficiency, Chronic; Severity of Illness Index; Simvastatin; Vascular Diseases | 2016 |
4 other study(ies) available for ezetimibe and Vascular Diseases
| Article | Year |
|---|---|
Combination Therapy with Ezetimibe: An Alternative Strategy to Statin Monotherapy in the Management of Patients with Non-cardiac Vascular Disease.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Treatment Outcome; Vascular Diseases | 2022 |
Endoplasmic reticulum stress effector CCAAT/enhancer-binding protein homologous protein (CHOP) regulates chronic kidney disease-induced vascular calcification.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Azetidines; Calcinosis; Cardiovascular Diseases; Case-Control Studies; Drug Therapy, Combination; Endoplasmic Reticulum; Ezetimibe; Humans; Ketocholesterols; Lipids; Male; Mice, Inbred C57BL; Mice, Knockout; Middle Aged; Renal Insufficiency, Chronic; Simvastatin; Transcription Factor CHOP; Vascular Diseases | 2014 |
[The use of complex tools ezetimibe, hepadyfu fosinopril and correction of blood pressure and endothelial dysfunction in patients with nonalcoholic steatohepatitis and essential hypertension stage II].
Topics: Adenine; Anticholesteremic Agents; Azetidines; Carnitine; Drug Combinations; Endothelium, Vascular; Essential Hypertension; Ezetimibe; Fosinopril; Humans; Hypertension; Non-alcoholic Fatty Liver Disease; Obesity; Vascular Diseases | 2014 |
Effects of ezetimibe add-on to statin therapy on adipokine production in patients with metabolic syndrome and stable vascular disease.
Topics: Adipokines; Aged; Anticholesteremic Agents; Azetidines; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metabolic Syndrome; Middle Aged; Vascular Diseases | 2010 |